AZN
The headline: growth, not vibes
AstraZeneca came out swinging with full-year 2025 results that look pretty darn healthy. Total revenue climbed 9% to $58.7 billion, while core EPS rose 11% to $9.16. That’s the kind of report that tells investors the engine is still humming, not just coasting downhill on one blockbuster drug.
Why the market should care
The growth wasn’t coming from one magic bean. AstraZeneca said Oncology, CVRM, R&I, and Rare Disease all helped push sales higher, which is what you want to see if you’re trying to avoid the classic pharma problem of “one drug to rule them all.” The company also said Q4 revenue rose 4% to $15.5 billion, so the momentum didn’t fade at the finish line.
The cherry on top: the dividend
AstraZeneca also increased its total declared FY 2025 dividend by 3% to $3.20 per share. In plain English: management is basically saying, “We’ve got cash coming in, and we’re willing to share a little more of it.” For income-focused investors, that’s not nothing.
Pipeline, pipeline, pipeline
The company also highlighted 16 positive Phase 3 readouts and 43 approvals across major regions during the year. That matters because pharma stocks are part business, part science fair — and the science fair needs to keep winning if future revenue is going to keep showing up.
Looking ahead, AstraZeneca expects mid-to-high single-digit revenue growth in FY 2026 and low double-digit core EPS growth. Big picture: the company isn’t just posting a good year — it’s telling you the next one could be solid too.